Rhythm Pharmaceuticals Shares Surge Following Report of AstraZeneca Acquisition Bid
Shares of Rhythm Pharmaceuticals (RYTM) rose 22% following reports that pharmaceutical giant AstraZeneca (AZN) has made a significant acquisition attempt. According to the Wall Street Journal, AstraZeneca extended an offer of approximately $124 per share last month, valuing the biotech firm at nearly $10 billion. The potential buyout highlights growing interest in specialized biotechnology assets as major pharmaceutical companies look to expand their pipelines. While the report focuses on a previous offer made last month, the market reaction reflects investor anticipation regarding a possible deal or further negotiations between the two entities.
Topics: M&A Pharmaceuticals Stock Surge
Read the full article at Seeking Alpha
Part of the story Helen of Troy Shares Surge Following Takeover Bid from Spectrum Brands Unit (2 articles)